New drugs recast $10 billion hemophilia market as Sanofi swoops in

LONDON (Reuters) - Sanofi is placing a big bet on the $10 billion-a-year hemophilia market at a testing time, as scientific advances overhaul traditional approaches to treating the rare uncontrolled bleeding disorder.